Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Cannabist

Biotech & Life Sciences · New York City, United States · Founded 2012 · IPO 2019 Thoroughbred

Patient-center healthcare company setting th standard of care for medical marijuana

Valuation
$444M
Market cap · 2026
Revenue
$459M
Latest reported FY
EBITDA
$55M
Latest reported FY

Global footprint

Where Cannabist has talent and traffic

Workforce by country
1 countries with
team presence
🇺🇸 United States99.3%
1 country shown
Web traffic by country
420 monthly visits
across markets
🇺🇸 United States95.2%
Top 1 markets shown

Capital deployed

Cannabist's 6 investments and acquisitions.

Every disclosed deal where Cannabist appeared as a backer or acquirer, 2019–2021. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

6 deals across Cannabist's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Cannabist's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        6 of 6 deals

        Market sentiment

        What the market is saying about Cannabist

        An AI-synthesized read of the highest-engagement posts about Cannabist on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Cannabist on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.